Why Ablation of Sites With Purkinje Activation Is Antiarrhythmic: The Interplay Between Fast Activation and

Ruben Coronel1,2, Mark Potse2,3,4, Michel Haïssaguerre2

  • 1Department of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Insights

Ablating Purkinje activity can treat idiopathic ventricular fibrillation (iVF). Deeper Purkinje network activation may cause arrhythmias, suggesting reduced penetrance as a therapeutic target for iVF.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Cardiac Anatomy

Background:

  • Idiopathic ventricular fibrillation (iVF) is a life-threatening arrhythmia.
  • Ablation targeting Purkinje activity shows antiarrhythmic effects in some iVF patients.
  • The precise mechanism underlying successful Purkinje ablation for iVF remains unclear.

Purpose of the Study:

  • To investigate the role of Purkinje network penetrance in the pathophysiology of iVF.
  • To elucidate the mechanism by which Purkinje activity contributes to ventricular arrhythmias.
  • To identify potential therapeutic targets for iVF based on Purkinje network characteristics.

Main Methods:

  • The study proposes a mechanistic hypothesis involving Purkinje network anatomy and ventricular activation.
  • Analysis of electrophysiological data and cardiac models to assess the impact of Purkinje penetrance on propagation velocity and arrhythmogenesis.
  • Exploration of the relationship between Purkinje network depth, repolarization gradients, and arrhythmia induction.

Main Results:

  • Deeper Purkinje network penetrance is hypothesized to facilitate faster ventricular activation.
  • This accelerated activation, particularly with steep repolarization gradients, is proposed to be proarrhythmic.
  • Reducing Purkinje penetrance may decrease apparent propagation velocity, potentially mitigating arrhythmogenic substrate.

Conclusions:

  • The extent of Purkinje network penetration influences ventricular activation patterns.
  • Altered Purkinje network properties, specifically deeper penetrance, may contribute to the proarrhythmic state in iVF.
  • Modulating Purkinje network penetrance represents a potential therapeutic strategy for managing iVF.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.2K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.4K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.5K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.2K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.9K